From sickle cell cures to climate-resilient crops — gene editing is rewriting biology. Understand the science and the stakes.
Apr 22, 20264 min listen2 chapters
What you'll learn
How CRISPR-Cas9 works at the molecular level
Approved therapies and what is in clinical trials
Agricultural applications and food security
The ethical boundaries being debated globally
1. What CRISPR-Cas9 actually does
note
CRISPR Explained: How Gene Editing Works
From sickle cell cures to climate-resilient crops — gene editing is rewriting biology. Understand the science and the stakes.
note
CRISPR-Cas9 in one sentence
CRISPR-Cas9 is a programmable DNA-cutting system that uses a guide RNA to bring the Cas9 enzyme to a matching DNA sequence near a PAM site.
The molecular parts
Guide RNA: the address label
Cas9: the enzyme that cuts DNA
PAM: a short DNA motif Cas9 must see before it cuts
Repair pathways: the cell’s own editing machinery
Why it matters
The edit happens because the cell repairs the cut. That makes CRISPR a biological tool, not a self-contained machine.
diagram
equation
If the cut is repaired by non-homologous end joining, then ΔDNA≈1 to 20 bases is common, though larger deletions can occur.
note
A useful analogy
Think of Cas9 as a GPS-guided paper cutter. The guide RNA tells it where to go. The PAM is the safety check that says, “this is a valid cutting zone.”
2. From a cut to a therapy
note
Approved CRISPR therapies
Casgevy was the first CRISPR-based therapy approved by the FDA, in December 2023. It treats sickle cell disease and transfusion-dependent beta thalassemia.
What Casgevy edits
The therapy edits a regulatory region tied to BCL11A in blood stem cells. That reactivates fetal hemoglobin, which helps red blood cells avoid sickling.
Why ex vivo editing is easier
Cells are removed, edited, tested, and then infused back. That gives clinicians more control over the dose, the target cells, and quality checks before treatment.
chart · bar
Gene therapy strategies
Transcript
Welcome to Slate. Today we're looking at CRISPR Explained: How Gene Editing Works. We'll cover How CRISPR-Cas9 works at the molecular level, Approved therapies and what is in clinical trials, Agricultural applications and food security, and The ethical boundaries being debated globally. Let's get into it.
A cell’s DNA is a long instruction manual. CRISPR-Cas9 works like a search tool plus a pair of molecular scissors. The guide RNA is the search term. Cas9 is the cutter. When the guide matches a target sequence beside a short DNA tag called PAM, Cas9 opens the DNA and cuts both strands. In the common Streptococcus pyogenes Cas9, that PAM is NGG, where N can be any base. That small detail matters, because without the right PAM, Cas9 usually ignores the site. Here’s the key idea: the cut is not the edit. The cell makes the edit while repairing the break. If the cell uses non-homologous end joining, it often leaves small insertions or deletions. Those can knock out a gene. If researchers supply a repair template, the cell can use homology-directed repair to make a precise change, but that pathway is less active in many adult cells. The diagram shows why CRISPR is so flexible. One protein can be redirected to many genes just by changing the guide RNA. That is very different from older tools like zinc-finger nucleases or TALENs, which had to be re-engineered protein by protein. CRISPR was adapted for editing after key 2012 papers by Jennifer Doudna, Emmanuelle Charpentier, Feng Zhang, and colleagues. The Nobel Prize in Chemistry followed in 2020. The power comes from simplicity, but the same simplicity also creates risk: if the guide binds the wrong sequence, the cut can land in the wrong place.
The first approved CRISPR medicines show how the biology becomes medicine. In December 2023, the U.S. Food and Drug Administration approved Casgevy, also called exagamglogene autotemcel, for sickle cell disease and transfusion-dependent beta thalassemia. The treatment edits a patient’s own blood stem cells outside the body. It turns down a genetic switch called BCL11A enhancer so fetal hemoglobin comes back on. That matters because fetal hemoglobin can carry oxygen without the sickling problem caused by mutant hemoglobin S. The patient then receives the edited cells after conditioning chemotherapy. In other words, the edit is ex vivo: cells out, edited in the lab, then returned. That is safer than trying to edit inside the body, where delivery is much harder. The second approved therapy, Lyfgenia, was also approved in December 2023 for sickle cell disease, but it uses a lentiviral gene-addition approach rather than CRISPR. That distinction is important. Not every gene medicine is gene editing. In clinical trials, researchers are testing in vivo CRISPR for transthyretin amyloidosis, hereditary angioedema, and high LDL cholesterol. Early human data from NTLA-2001 showed a dose-dependent drop in transthyretin protein after a single infusion, which is striking because it suggests one treatment might have long-lasting effect. But delivery remains the bottleneck. Lipid nanoparticles and viral vectors each have tradeoffs in tissue targeting, immune response, and repeat dosing. The chart shows the difference between approved ex vivo editing and still-emerging in vivo approaches.